• Selexis SA and BITT Enter Service Agreement contractpharma
    March 11, 2021
    Selexis SA and Boston Immune Technologies and Therapeutics (BITT) have entered into a service agreement to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and ...
PharmaSources Customer Service